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Introduction
Parkinson's disease (PD) is a common neurolog-
ical disorder with progressive degeneration of
dopaminergic (DA) neurons in substantia nigra pars
compacta that is a cause of the main neurological
signs associated with PD. Among many animal mod-
els of PD, the experimental lesion of nigrostriatal sys-
tem by 6-hydroxydopamine (6-OHDA) is an excellent
model for the study of the adaptive mechanism in
response to the loss of DA neurons and for testing
pharmacologically active compounds and agents (1).
6-OHDA is a neurotoxin relatively specific for the ca-
techolaminergic neurons and its functional effects de-
pend on both total dose and the site of the injection (1
’3). Behavioral and neurodegenerative changes fol-
lowing partial lesions of the nigrostriatal dopamine
system in the rat, indicate that the four-site intrastriatal
6-OHDA lesion (with 70’80% destruction of DA neu-
rons) may be a relevant model of the neuropathology
seen in parkinsonian patients (2, 4’5).
Unilateral 6-OHDA lesion induces behavioral
stereotypies, as well as cellular and molecular modifi-
cations in the striatal target tissue, on the dopamine
(DA) and dopamine receptor (DA R) levels (6’7). The
actions of dopamine are mediated via five different
receptor subtypes which are the members of two
dopamine receptor classes, D1-like and D2-like. The
D1-like receptors include the D1 and the D5 receptor
and D2-like receptors include the D2 (with D2long and
D2short isoforms), D3 and D4 receptor. The D1 and
D2 receptors are the most abundant subtypes in the
central nervous system (CNS) and display specific
anatomical distribution (8). Although, there are still
controversies about co-localization of D1 and D2 re-
ceptors, they are mostly present in nonoverlapping,
medium-sized, spiny projection neurons throughout
the dorsal and ventral striatum. These neurons form
the two major output pathways of the striatum and the
balance between these pathways is crucial for the nor-
mal functioning of the basal ganglia (9’10). Lesions of
the dopamine system, such as those occurring in PD,
disrupt this balance and lead to the changes in the DA
receptor number and sensitivity. 
In this paper, we investigated the effects of four
site intrastriatal 6-OHDA lesions in adult male rats on
behavioral stereotypies and changes in the D1 and D2
receptor mRNA levels at early time points after the
lesions, since these changes haven't been extensively
studied so far. 
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Summary: The effects of four-site intrastriatal 6-hydroxydopamine (6-OHDA) lesions were examined in
adult male rats. Five days after the lesions the animals were checked for specific rotational behavior induced by
middle dose of amphetamine and the results confirmed the effectiveness of the lesions. The RNAs from the stria-
tum were isolated at different time points after the lesion, and the RT-PCR analyse were performed for the D1 and
D2 receptor mRNA. The results show a decline in the D2 receptor mRNA level (40%) at 6 h and 24 h points while
this change was not observed seven days after the lesion. In contrast, no statistically significant changes in the
level of the D1 receptor mRNA after the lesion at any time point were found.
Key words: Parkinsonian rats, 6-OHDA lesions, behavior, D1 and D2 mRNA, RT-PCR.
Material and methods
Animals and surgical procedures
Adult Mill-Hill hooded male rats, three months
old (200’300 g), were housed 2’4 per cage with a
12:12 hour light-dark cycle, at 22±2 °C. Food and
water were provided ad libitum. The animals anes-
thetized with thiopental (50 mg per kg i.p.) received
four unilateral stereotaxic injections of 6-OHDA, 4 ×7
mg in a volume of 8 mL, into the right striatum, using a
10-mL Hamilton micro syringe fitted with a 26-gauge
still cannula. Coordinates are:  AP: +1.3 +0.4 ’0.4
’1.3, ML: ’2.6 ’3.0 ’4.2 ’4.5, DV ’5.0 mm according
to the Paxinos and Watson atlas (5, 11). The 6-hydrox-
ydopamine-hydrobromide (ICN Pharmaceuticals, CA,
U.S.A.) was dissolved in ice-chilled 154 mmol/L NaCl
with 10 g/L ascorbic acid added to retard the oxidation
and the solution was kept cold and protected from
exposure to light, during the experiment. The injection
rate was 1 mL/min. After each 2 mL of 6-OHDA solu-
tion, the cannula was allowed to remain in the brain for
2 min. The incision was closed and treated with antibi-
otic. Control rats were injected with 10 g/L ascorbic
acid in 154 mmol/L NaCl solution.
Behavioral analysis
One week before the lesion, all animals were
tested for rotational behavior induced by middle dose
of amphetamine (3 mg/kg). Fifteen min after i.p injec-
tion, rotations were monitored in animal cage for 10
min, and right (CR) and left (CCR) full body turns were
observed. Five days after the lesion, the same behav-
ioral experiment was repeated in 6-OHDA-lesioned
and control animals, to confirm the effectiveness of
the lesion.
RNA isolation
Animals were divided into three experimental
groups and sacrificed at different time points after the
lesion and the brains were quickly removed. RNA was
isolated by the guanidine isothiocyanate (GTC)/cesium
chloride (CsCl) centrifugation method (12’14). Seven-
ten striata, left and right separately, were homogenized
in 7 mL of GTC puffer containing 4 mol/L GTC, 40 g/L
N-lauryl sarcosine, 50 mmol/L Na-acetate, pH 5.5 and
10 g/L b-mercaptoethanol. Dry CsCl, 0.5 g/mL, was
added to the homogenate and then layered on 3 mL
of CsCl, density of 1.7 g/cm3, for ultracentrifugation
(24 h, 38 000 rpm in a Ti-50 rotor). The obtaining pel-
lets were suspended in precipitation buffer containing
10 mmol/L Tris-HCl, pH 7.5, 1 mmol/L EDTA and 5
g/L SDS. After butanol/chlorophorm extraction, the
pellets were suspended in one volume of 3 mol/L Na-
acetate, pH 5.0 and two volumes of absolute cold
ethanol and kept overnight at ’20 °C. The solutions
were centrifuged (20 min, 10 000 rpm) and the pellets
were suspended in DEPC-treated water and kept at
’70 °C . 
Reverse transcription (RT)
For the synthesis of cDNAs, 5 mg of total RNA
was reverse transcribed in RT buffer (containing 50
mmol/L KCl, 10 mmol/L TRIS-HCl, pH 8.3, 5 mmol/L
MgCl2) 100 mmol/L DTT, 2.5 mmol/L Oligo (dT)16,
dNTPs 0.5 mmol/L each, 1 U RNase inhibitor and 2.5
U of murine leukemia virus reverse transcriptase
(MuLV RT) in a final volume of 10 mL. The reaction
cycle consisted of 1 h at 42 °C, 10 min at 95 °C, then
cooling to 5 °C. The cDNAs were kept at ’20 °C. To
minimize errors in pipetting among the samples, mas-
ter mixes of cDNA synthesis buffer containing the
dNTPs, RT buffer, oligo (dT), DTT and the enzymes
were prepared and used for RT of all RNA samples in
experiment.
PCR assay
For PCR amplification, appropriate dilutions of
cDNA samples representing 100’200 ng of total RNA
were mixed with PCR buffer containing 100 mmol/L
dNTPs, 1.5 mmol/L MgCl2, Stoffel Buffer (containing
50 mmol/L KCl and 10 mmol/L Tris-HCl), 0.8’1 mmol/
L each of the primers and 1.25 U Stoffel Taq polyme-
rase in a total volume of 25 mL. 
A PCR primer pair for D1, D2, b-actin, and cyclo-
philin (p1B15) sequences, obtained from Gene Bank,
were used to design the primer pairs. All oligonu-
cleotide primer pairs spanned the intron/exon splice
site, ensuring that PCR products did not arise from
DNA contamination present in the RNA preparations.
The amplification products were normalized against
the »housekeeping« gene b-actin, and cyclophilin
(p1B15). The primer sequences and PCR product size
were as follows:
D1, amplifying sequences corresponding to ami-
no acid residues 235’310 of the D1 cDNA, with PCR
product 225 bp long (15):
5'-CAGTCCATGCCAAGAATTGCC-3' and
5'-AATCGATGCAGAATGGCTGGG,
D2, amplifying sequences corresponding to
amino acid residues 228’362 of the D2 long cDNA,
which will amplify both D2 long- and D2 short-specif-
ic fragments. Specifically, the primers anneal on either
side of the alternative splice site and therefore gene-
rate two different fragments following PCR of 404 bp
and 317 bp, respectively (15):
5'-GCAGTCGAGCTTTCAGAGCC-3' and
5'-TCTGCGGCTCATCGTCTTAAG-3'
Cyclophilin -p1B15 (16)
5'-AGAAGCGCATGAGCATTGTGGAAG-3' and
5'-TGCTCTCCTGAGCTACACAGAAGGAA-3' (195 bp)
b-actin (17)
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5'-CAGCCATGTACGTTGCTATCCAG-3' and 
5'-GTTTCGTGGATGCCACAGGAC-3'(415 bp)
The samples were denatured initially at 94 °C for
2 min and amplification was performed. Cycle param-
eters in all cases were:  94 °C for 1 min, 55 °C for 1
min and 72 °C for 1 min (30 cycles) followed by 72 °C
for 8 min. PCR amplified products were analyzed by
electrophoresis in a 18 g/L agarose gel. All PCRs were
performed at least five times. The levels of D1 mRNA
were compared and a correction was made for differ-
ences in b-actin mRNA. The levels of D2 mRNA were
compared and corrected with p1B15 mRNA levels.
Statistical analyses
For the PCRs, relative signal intensities were cal-
culated and the data presented as the mean ± SEM.
A one-way analysis of variance (ANOVA), followed by
the Tukey test was used for statistical comparisons
between the groups. A probability value equal or less
then 0.05 (5%) was considered statistically significant.
Results
In order to determine whether the observed rota-
tions of the rats were due to 6-OHDA lesions, turning
behavior was measured in presence of amphetamine.
The data on full body turns per 10 min, before the
lesion and five days after the lesion are presented in
Figure 1. Before the lesion, there was no statistically
significant difference between ipsilateral and contrala-
teral rotation among the animals (Fig.1a, d). Still, five
days after the lesion, control animals did not express
any changes comparing to rotation before the lesion
(Fig. 1b, e). However, the rats bearing unilateral 6-
OHDA lesions demonstrated a statistically significant
increase (4 times) in ipsilateral rotation (Fig.1c). In
contrast, a significant decrease in contralateral rota-
tion was observed five days after the lesion (Fig.1f). 
To see whether the 6-OHDA lesions cause the
changes on the level of DA receptors, the expression
of the D1 and D2 mRNA was examined. We perfor-
med semi-quantitative RT-PCR assay using primers
designed on the basis of the sequences of the D1 and
D2 gene. 
To assess the changes in D1 mRNA expression,
cDNA from different time points (6 h, 14 h, and 7
days) and treatment, were used in the assay to co-
amplify either D1 or b-actin mRNAs. As shown in Fi-
gure 2A, the specific amplified product for D1 recep-
tor mRNA is 225 bp. Densitometric analysis of the
agarose gel with PCR products revealed no differences
in the level of D1 mRNA following different time points
and treatment (Fig. 2 B,C,D). Statistical analysis using
ANOVA followed by the Tukey test confirmed these
results.
In the case of the D2 receptor, two forms gene-
rated by alternative splicing amplified different frag-
ments of 404 bp and 317 bp, (long and short form)
corresponded to the molecular size of the D2 mRNA.
The agarose gel with PCR products for the D2 recep-
tor and cyclophilin mRNAs are presented in Figure 3A.
There was a significant difference between the control
and treated group of animals (p < 0.05) in the level of
long form D2 receptor mRNA (40%), 6 and 24 h after
the lesion on the right side (Figure 3 B,C). Seven days
after the lesion, no statistically significant differences
in D2 long form mRNA on the lesioned side were
observed (Figure 3D). We also examined the effect of
6-OHDA lesion on the level of the short form D2
receptor mRNA. As shown in Figure 3 B,C,D, the
short form was also significantly changed for the right
and left side of the treatment and between the controls
and the treatments, as well. Statistical analysis using
ANOVA followed by the Tukey test confirmed these
results.
Jugoslov. Med. Biohem. 2002.; 21 (3) 277
Figure 1   The effect of unilateral, four-site 6-OHDA 
lesion on rotational behavior of rats. 
a-clock rotations (CR) before the lesion; b-CR five days
after the lesion in control animals; c-CR five days after the
lesion in 6-OHDA treated animals; d-contra clock rotations
(CCR) before the lesion; e-CCR five days after the lesion
in control animals; f-CCR five days after the lesion 
in 6-OHDA treated animals. Rotational behavior induced
by middle dose of amphetamine (3 mg/kg) was monitored
during  10 minutes. The data are mean ± S.E.M. obtained
from at least three separate experiment repeats under 
the same conditions. Kruskal-Wallis One Way ANOVA 
and Dunn's method of multiple comparisons versus 
control group were used.
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Discussion 
6-Hydroxydopamine (6-OHDA) is the most
prevalent monoaminergic toxin in degeneration of
dopaminergic neurons and has been used extensively
in animal models of Parkinson's disease (PD). Dege-
neration of the nigrostriatal dopamine pathway results
in an imbalance in the activity of direct and indirect
pathways between the striatum and the output nuclei
of the basal ganglia, which is responsible for move-
ment disorder associated with PD. This imbalance is a
consequence of the segregation of the D1 and D2
dopamine-receptor subtypes on the direct and indirect
striatal projection neurons (8’9).
Though long-term changes in the level of the DA
receptors induced by 6-OHDA lesions have been
extensively studied, early lesion-induced changes and
the time course of these changes have received rela-
tively little attention. These changes are of great inte-
rest because of slow and progressive course of Parkin-
son's disease.
The results presented in this paper demonstrate
that four-site intrastriatal injection of 6-OHDA induced
early and fast changes in the level of D2R mRNA in the
striatum, as a consequence of lesion and postsynaptic
adaptations that occur in the striatum, but the chan-
ges in D1R mRNA were not statistically significant at
these early time points.
Five days after the lesion, middle dose of amphe-
tamine, which increases synaptic levels of DA by in-
ducing its release from, and inhibiting its reuptake into
intact terminals, induced ipsiversive rotation (turning is
ipsilateral to the lesion), as a result of a greater DA re-
ceptor stimulation on the intact side (18’20).
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Figure 2   RT-PCR assay of  the D1 mRNA  in control and 6-OHDA-treated rats at different time points.
A- The PCR products for D1R (225 bp) and b-actin (415 bp) were separated on 15 g/L agarose gel stained with ethidium br
mide and  photographed under UV  light. Quantification was carried out using Multi-Analyst/PC Software Image Analysis
System (Bio-Rad, Gel Doc 1000).  M-Molecular weight marker (100 bp DNA ladders). 1 ’ the PCR products from the left 
striata of control animals; 2 ’ the PCR products from  the left striata of 6-OHDA-treated animals; 3 ’ the PCR products from
the right striata of control animals; 4 ’ the PCR products from the right striata of 6-OHDA-treated animals. B-Quantitative
analysis of the D1R mRNA expression in control and 6- OHDA-treated animals 6  h after the lesion; C-Quantitative 
analysis  of the D1R mRNA expression  in control and 6-OHDA-treated animals 24  h after the lesion;  D-Quantitative  
analysis of D1R mRNA expression in control and 6-OHDA-treated animals 7 days after the lesion. Changes in the D1R mRNA
levels were obtained as a ratio of the D1R  mRNA  and b-actin mRNA levels. 1 ’ relative level of the D1R mRNA in the left 
striata of control animals; 2 ’ relative level of the D1R mRNA in the left striata of 6-OHDA-treated animals; 3 ’ relative level
of the D1R mRNA in the right striata of control animals; 4 ’ relative level of the  D1R mRNA in the right striata 
of 6-OHDA-treated animals. The data represent the means ± S.E.M. for minimum 5 repeats per given time point. 
One Way ANOVA with Tukey Test were used.
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Proliferation of DA receptors (particularly D2 re-
ceptors) has been proposed as the cell-level mecha-
nism responsible for this behavioral supersensitivity
and recovery of function, but increase in the density of
striatal DA receptors has usually been reported to
occur two or more weeks post lesion (21’24). Other
studies using in vivo binding methods have, however,
reported proliferation of D2 receptors as early as 4
days after 6-OHDA injection (25’26).
Our results show that 6 h and 24 h after the
lesion there is a decrease in  D2 receptor mRNA level,
probably as a consequence of the mechanical de-
struction of striatal neurons  bearing D2 receptors and
as a result of degeneration of dopaminergic fibers that
are also bearing these receptors. The differences that
exist in time-dependent changes between D2 short
and D2 long form may be explained by the differences
in the distribution or regulation of the two forms (27’
28). Seven days after the lesion, as a result of D2 re-
ceptor proliferation, there was no statistically signifi-
cant difference between the control and treated ani-
mals.
However, colocalization of the D1 and D2 recep-
tors on striatal neurons and 6-OHDA-induced chan-
ges in D1 receptors remain controversial. Many aut-
hors suggest that nearly one-half of all medium spiny
neurons bear both types of the receptors (29’33), whi-
le the others find that D1 and D2 receptors appear to
be expressed largely in distinct neurons (34’36). Sa-
vasta (21) and Flores (36) found that as compared to
the intact side, the 6-OHDA lesions did not change the
D1 receptor. According to Araki et al (23’24), unilat-
eral injection of 6-OHDA in the medial forebrain bun-
dle can cause a significant increase in the D1 receptor
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Figure 3   RT-PCR assay of D2 mRNA (both forms) in control and 6-OHDA-treated  rats at different time points. 
A-The PCR products for D2R (404 and 317 bp) and cyclophilin (159 bp) were separated on 15 g/L agarose gel stained with
ethidium bromide and photographed under UV light. Quantification was carried out using Multi-Analyst/PC Software Image
Analysis System (Bio-Rad Gel Doc 1000).  M- Molecular weight marker (100 bp DNA ladders). 1 ’ the PCR products 
from the left striata of control animals; 2 ’ the PCR products from the left striata of 6-OHDA-treated animals; 3 ’ the PCR
products from the right striata of control animals; 4 ’ the PCR products from the right striata of 6-OHDA-treated animals.  B-
Quantitative analysis of the D2R mRNA expression in control and 6-OHDA-treated animals 6 h after the lesion; C- Quantitative
analysis of  the D2R mRNA expression in control and 6-OHDA-treated animals 24  h after the lesion; D- Quantitative analysis
of the D2R mRNA expression in control and 6-OHDA-treated animals 7 days after the lesion. Changes in the D2R mRNA 
levels were obtained as a ratio of the D2R  mRNA and cyclophilin  mRNA levels. 1 ’ relative level of the D2R mRNA in 
the left striata of control animals; 2 ’ relative level of the D2R mRNA in the left striata of 6-OHDA-treated animals; 
3 ’ relative level of the D2R mRNA in the right striata of control animals; 4 ’ relative level of  the D2R mRNA in the right striata 
of 6- OHDA-treated animals. The data represent the means ± S.E.M. for minimum 5 repeats per given time point.
One Way ANOVA  with Tukey Test were used.
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in the striatum from 2 to 4 weeks of post-lesion, but
this change is less pronounced than that in dopamine
D2 receptor. Gerfen et al (37) even found a 6-OHDA-
induced reduction in D1R mRNA. Our result suggests
that there are no statistically significant changes in the
level of the D1 receptor mRNA during the first postop-
erative week. One possible explanation is a heteroge-
neous fashion of dopamine system degeneration fol-
lowing 6-OHDA administration (38) and a probability
that neurons that bear only D1 receptors are probably
less susceptible to 6-OHDA action or that these neu-
rons require more time for molecular adaptations. A
slight increase in the level of the D1R mRNA seven
days after the lesion supports such an idea.
A slight increase in the DA-receptor synthesis
and sensitivity seems to be insufficient to compensate
for a decline in amphetamine-induced DA release five
days after the lesion and rotational asymmetry.
However, it might be that at this time point an increase
in DA receptor synthesis just begain. Fornaguera (20)
also observed ipsilateral asymmetry in turning first day
after the lesion, but one week later the animals
expressed a tendency to recover from deficit as a con-
sequence of compensatory mechanism in the stria-
tum.
Striatal dopamine receptor supersensitivity deve-
loped only when 90% or more of striatal DA nerve ter-
minals have been destroyed (39). At this stage, all
main signs of parkinsonism become visible. Because
of that, the investigation of early changes in the D1
and D2 receptor synthesis may provide a better insight
into movement disorder characteristic for PD and may
help in developing of novel therapeutic strategies.
Acknowledgments
This work was supported by grant 1641 from the
Ministry for Science, Technology and Development of
the Republic of Serbia.
280 Jugoslov. Med. Biohem. 2002.; 21 (3)
6-HIDROKSIDOPAMINSKA LEZIJA STRIATUMA IZAZIVA PROMENE iRNK 
ZA DOPAMINSKE RECEPTORE KOD PARKISONI^NOG PACOVA
Aleksandra Mladenovi}, Milka Perovi}, Desanka Milanovi}, Selma Kanazir, Ljubisav Raki}, Sabera Ru`diji} 
Odeljenje za neurobiologiju i imunologiju, Laboratorija za molekularnu neurobiologiju
Institut za biolo{ka istra`ivanja  »Sini{a Stankovi}«, 29. novembra 142, 11060 Beograd, Srbija
Kratak sadr`aj: Kratak sadr`aj: Ispitivani su efekti ~etiri ubodne 6-hidroksidopaminske (6-OHDA) lezije
striatuma kod odraslih mu`jaka pacova. Pet dana nakon lezije, `ivotinje su testirane na specifi~no rotaciono po-
na{anje pod uticajem srednje doze amfetamina i rezultati su potvrdili efikasnost lezije. RNK iz striatuma su izolo-
vane u razli~itim vremenskim ta~kama nakon lezije i ura|ena je RT-PCR analiza iRNK za D1 i D2 dopaminske
receptore. Rezultati pokazuju smanjivanje nivoa iRNK za D2 receptor (40%) 6 h i 24 h nakon lezije, dok sedam
dana nakon lezije nema promena. Za razliku od ovih rezultata, u nivou iRNK za D1 receptor ne postoje statisti~ki
zna~ajne razlike u bilo kojoj vremenskoj ta~ki.  
Klju~ne re~i: parkinsoni~an pacov, 6-OHDA lezija, pona{anje, dopaminski receptori, iRNK za D1R i D2R,
RT-PCR.
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